Lupin ties up with China’s Fancoo Pharma

“Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality products”

January 19, 2022 12:35 pm | Updated 12:35 pm IST - Mumbai

File photo for representation

File photo for representation

Lupin Ltd., a pharmaceutical company, said it has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd (Fancoo) of China to market its generic & complex generic medicines in that country.

This is Lupin’s first partnership arrangement in China.

Dr. Fabrice Egros, President, Growth Markets, Lupin said, “Lupin continues to invest in key growth markets. With China’s growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality generic and complex generic products.”

“We are very excited about our partnership with Foncoo. We will continue exploring additional partnership opportunities in China to leverage our global portfolio including complex generics and specialty medicines,” he said.

Peng Yan, General Manager, Foncoo said, “Foncoo’s successful experiences on importing registration and marketing of the generic formulations and Lupin’s strong capability of making high-quality medicines make our perfect match to each other and our collaboration will most likely have a bright future.”

“We expect that the successful launch of our first product in China will come smoothly and soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-value and complex medicines to the Chinese physicians and patients,” he added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.